Denise Yardley, MD
The de-escalation of therapy has been a continuing theme in much of the breast cancer treatment landscape over the last year. Multiple trials from the 2018 ASCO Annual Meeting addressed this, as well as provided options for physicians who want to move away from chemotherapy, according to Denise A. Yardley, MD.
On the other end of the spectrum, the first results from the phase III placebo-controlled D-CARE study were unexpected, Yardley said. Findings showed that in patients with early breast cancer undergoing locoregional and standard system adjuvant therapy, denosumab did not reduce breast cancer recurrence.3
Additionally, results with the PARP inhibitor talazoparib from the EMBRACA trial presented at the 2017 San Antonio Breast Cancer Symposium have sparked interest, Yardley said. Talazoparib reduced the risk of disease progression or death by 46% versus chemotherapy in patients with BRCA
-positive advanced breast cancer.4
This led to the FDA granting a priority review designation for the PARP inhibitor in patients with HER2-negative locally advanced or metastatic breast cancer with germline BRCA
... to read the full story